Skip to main content
Mirati Therapeutics Inc. logo
  • Investors & Media
    • Overview
  • Careers
  • Contact Us
  • Home
  • Science
    • Pipeline
    • Programs
      • KRAS
        Inhibitors
        • KRASG12C
          Inhibitor
        • KRASG12D
          Inhibitor
      • Sitravatinib
    • Clinical Trials
    • Presentations &
      Publications
  • Patients
  • Impact
  • Stories
  • About
    • Executive
      Leadership
    • Board of Directors
    • Business
      Development
    • Our Heritage
    • Home
    • Science
        Back
      • Overview
      • Pipeline
      • Programs
          Back
        • Overview
        • KRAS Inhibitors
            Back
          • Overview
          • KRAS G12C Inhibitor
          • KRAS G12D Inhibitor
        • Sitravatinib
      • Clinical Trials
      • Presentations & Publications
    • Patients
    • Impact
    • About
        Back
      • Overview
      • Executive Leadership
      • Business Development
      • Our Heritage
    • Investors & Media
        Back
      • Overview
    • Careers
    • Contact Us

Quarterly Results

  • Overview
    • Press Releases
    • Events &
      Presentations
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Governance
    • Resources
      • Investor FAQs
      • Information Request Form
      • Email Alerts
      • Investor Contacts
  • Overview
    • Press Releases
    • Events &
      Presentations
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Governance
    • Resources
      • Investor FAQs
      • Information Request Form
      • Email Alerts
      • Investor Contacts

Contact Us

Investor Relations

Temre Johnson
ir@mirati.com
(858) 332-3562

Media Relations

Priyanka Shah
media@mirati.com
(908) 447-6134

Quick Links

  • SEC Filings
  • Investor FAQs
  • Information Request Form

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Mirati Therapeutics Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Mirati Therapeutics Inc. to send you the requested Investor Email Alert updates.

* Required

*
*




Unsubscribe

Email Alert Sign Up Confirmation

Mirati Therapeutics Inc. logo

© Copyright - Mirati Therapeutics, Inc.

  • 858.332.3410
  • info@mirati.com
  • Twitter
  • Linkedin
  • Terms of Use
  • Privacy
  • Cookies
  • Expanded Access
  • Community Guidelines
Powered By Q4 Inc. 5.56.0.1 (opens in new window)